Management of spontaneous pneumothorax in patients with COVID-19

dc.authoridağar, mehmet/0000-0002-4129-766X
dc.authoridGulcek, İlham/0000-0001-6204-455X
dc.authoridKalkan, Muhammed/0000-0003-2952-3502
dc.authoridCelik, Muhammet Reha/0000-0001-8461-2909
dc.authorwosidağar, mehmet/IXX-0672-2023
dc.authorwosidGulcek, İlham/HHS-7311-2022
dc.contributor.authorUlutas, Hakki
dc.contributor.authorCelik, Muhammet Reha
dc.contributor.authorGulcek, Ilham
dc.contributor.authorKalkan, Muhammed
dc.contributor.authorAgar, Mehmet
dc.contributor.authorKilic, Talat
dc.contributor.authorGulcek, Emine
dc.date.accessioned2024-08-04T20:52:00Z
dc.date.available2024-08-04T20:52:00Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractOBJECTIVES: The coronavirus disease 2019 (COVID-19) pneumonia may cause cystic features of lung parenchyma which can resolve or progress to larger blebs. Pneumothorax was more likely in patients with neutrophilia, severe lung injury and a prolonged clinical course. The timely diagnosis and management will reduce COVID-19-associated morbidity and mortality. METHODS: We present 11 cases of spontaneous pneumothorax managed with chest tube thoracostomy or high-dose oxygen therapy. Isolated spontaneous pneumothorax was detected in all cases. RESULTS: Eight cases were male and 3 cases were female. There were bilateral ground-glass opacities or pulmonary infiltrates in the parenchyma of the 10 cases. We detected neutrophilia, lymphopaenia and increased C-reactive protein, Ferritin, lactate dehydrogenase, D-Dimer, interleukin-6 levels in almost all cases. Chest tube thoracostomy was sufficient to treat pneumothorax in our 9 of case. In 2 cases, pneumothorax healed with high-dose oxygen therapy. Favipiravir and antibiotic treatment were given to different 10 patients. In our institution, all patients with COVID-19 infection were placed on prophylactic or therapeutic anticoagulation, unless contraindicated. The treatments of patients diagnosed with secondary spontaneous pneumothorax during the pandemic period and those diagnosed with secondary spontaneous pneumothorax in the previous 3 years were compared with the durations of tube thoracostomy performed in both groups. CONCLUSIONS: The increased number of cases of pneumothorax suggests that pneumothorax may be a complication of COVID-19 infection. During medical treatment of COVID-19, pneumothorax may be the only reason for hospitalization. Although tube thoracostomy is a sufficient treatment option in most cases, clinicians should be aware of the difficulties that may arise in diagnosis and treatment.en_US
dc.identifier.doi10.1093/icvts/ivab280
dc.identifier.endpage1010en_US
dc.identifier.issn1569-9293
dc.identifier.issn1569-9285
dc.identifier.issue6en_US
dc.identifier.pmid34661670en_US
dc.identifier.scopus2-s2.0-85131269216en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1002en_US
dc.identifier.urihttps://doi.org/10.1093/icvts/ivab280
dc.identifier.urihttps://hdl.handle.net/11616/100693
dc.identifier.volume34en_US
dc.identifier.wosWOS:000790175900001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofInteractive Cardiovascular and Thoracic Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSpontaneous pneumothoraxen_US
dc.subjectCoronavirus disease 2019 pneumoniaen_US
dc.subjectChest tube thoracostomyen_US
dc.subjectGround-glass opacitiesen_US
dc.titleManagement of spontaneous pneumothorax in patients with COVID-19en_US
dc.typeArticleen_US

Dosyalar